Back to Business: Trump’s Return Sparks M&A Hopes on Wall Street

Wall Street appears to be warming up to Donald Trump's return to the Oval Office, anticipating a flood of merger and acquisition (M&A) activity as the business environment shifts gears once again. With Trump now back in the driver’s seat, dealmakers and CEOs are predicting that regulatory headwinds, which intensified under Biden's FTC, will soon die down. In short, the bulls are back on Wall Street, and they're ready to charge.

Why the Optimism?
Trump’s re-election—and the GOP taking control of the Senate—could mark a sharp pivot away from the tough antitrust scrutiny that defined the last four years. Under Biden’s administration, FTC Chair Lina Khan put the brakes on major deals, particularly in sectors like pharmaceuticals and tech, arguing that unchecked consolidation could stifle competition and hurt consumers. But now, as one M&A advisor quipped, “The hostile approach of the FTC to mergers will almost certainly be reset and replaced with a worldview that’s more favorable to corporate deal-making.”

Trump’s administration is expected to turn a lighter regulatory touch into policy, possibly even targeting specific industries for relief. For financial services and pharmaceuticals, this could be a game-changer. Companies like Kroger and Tapestry, whose proposed takeovers have been tied up in court battles, are suddenly finding themselves back in the game. The expectation is that a Republican-led FTC will be more inclined to rubber-stamp deals that were previously shelved.

Green Light for Big Deals
M&A activity had been in a lull, partly due to high interest rates and the Biden administration’s tight scrutiny of mergers. Now, Wall Street insiders are saying Trump's return might release a wave of deal-making in industries like healthcare, finance, and retail. Pharma executives, for instance, are especially bullish that regulatory hurdles will ease, paving the way for acquisitions that were once considered politically toxic.

The financial sector, too, is eager for consolidation, especially among regional banks. The need for scale in this high-interest-rate environment means that smaller banks are prime candidates for mergers. One industry insider noted that the landscape is ripe for a buying spree.

The Media and Tech Wildcards
While pharma and banking are optimistic, tech might not have it so easy. Trump's well-documented disdain for Big Tech could still keep giants like Google and Meta from making blockbuster deals. The GOP's opposition to subsidies for chipmakers could also slow semiconductor consolidations, despite the sector's hunger for scale.

Media companies, on the other hand, are eyeing the changing winds with a bit more optimism. David Zaslav, CEO of Warner Bros. Discovery, hinted that a Trump-led regulatory environment could breathe new life into media consolidations. Meanwhile, Sinclair Broadcasting is looking forward to lifting what it describes as a regulatory “cloud” over the industry.

What’s Next?
It’s clear that Wall Street is betting on a Trump-fueled resurgence in deal-making. The Dow has already surged on the news of Trump's win, climbing over 1,500 points in anticipation of a business-friendly White House. If Trump’s last term was any indication, we might see a swift rollback of regulations, potentially spurring another wave of mega-mergers.

However, whether this optimism will translate into actual deals remains to be seen. The Biden administration's legacy of antitrust enforcement has left its mark, and it’s unclear how quickly Trump’s team can undo those barriers. And while sectors like finance and pharma are ready to pounce, Big Tech may still find itself on the outside looking in.

So, while the champagne bottles are popping on Wall Street, let's not forget: optimism is easy when you're celebrating, but the devil is always in the regulatory details.
​